| Drug General Information |
| Drug ID |
D0O2JI
|
| Former ID |
DIB001398
|
| Drug Name |
Ertumaxomab
|
| Synonyms |
Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
|
| Drug Type |
Antibody
|
| Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Phase 2 |
[1],
[2]
|
|---|
|
Advanced breast cancer [ICD9: 174, 175; ICD10:C50]
|
Phase 1 |
[3]
|
| Company |
Trion
|
| CAS Number |
CAS 509077-99-0
|
| Target and Pathway |
| Target(s) |
CD3 |
Target Info |
|
[1],
[2]
|
|---|
| T-cell surface glycoprotein CD3 epsilon chain |
Target Info |
|
[1],
[2]
|
| Receptor protein-tyrosine kinase erbB-2 |
Target Info |
|
[1],
[2]
|
|
KEGG Pathway
|
Hematopoietic cell lineage
|
|
T cell receptor signaling pathway
|
|
Chagas disease (American trypanosomiasis)
|
|
Measles
|
|
HTLV-I infectionhsa04640:Hematopoietic cell lineage
|
|
HTLV-I infection
|
|
Primary immunodeficiencyhsa04012:ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
Leptin Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
T cell activationP00053:T cell activationP00012:Cadherin signaling pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
TCR signaling in naï
|
|
IL12-mediated signaling events
|
|
TCR signaling in naï
|
|
CXCR4-mediated signaling events
|
|
Downstream signaling in naï
|
|
IL12 signaling mediated by STAT4tcr_pathway:TCR signaling in naï
|
|
IL23-mediated signaling events
|
|
IL12 signaling mediated by STAT4erbb4_pathway:ErbB4 signaling events
|
|
ErbB2/ErbB3 signaling events
|
|
ErbB receptor signaling network
|
|
a6b1 and a6b4 Integrin signaling
|
|
Validated targets of C-MYC transcriptional repression
|
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
|
Reactome
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
FCGR activation
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Role of phospholipids in phagocytosis
|
|
PD-1 signalingR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
PD-1 signalingR-HSA-1250196:SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
TCR Signaling Pathway
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
TCR signaling
|
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Costimulation by the CD28 familyWP69:TCR Signaling Pathway
|
|
Costimulation by the CD28 familyWP710:DNA Damage Response (only ATM dependent)
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Bladder Cancer
|
|
Signaling by ERBB2
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. |
|---|
| REF 2 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. |
|---|
| REF 3 | ClinicalTrials.gov (NCT00452140) Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment |
|---|
